Resources from the same session
498O - INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma
Presenter: Deborah Blumenthal
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Invited Discussant 498O
Presenter: Dieta Brandsma
Session: Proffered Paper session - CNS tumours
Resources:
Slides
Webcast
499O - A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated
Presenter: Wenbin Li
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast
500O - Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study
Presenter: Maria Vieito Villar
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast
501O - Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Presenter: Maria Angeles Vaz Salgado
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 499O, 500O and 501O
Presenter: Anna Sophie Berghoff
Session: Proffered Paper session - CNS tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - CNS tumours
Resources:
Slides
Webcast